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Figure 1. Biopsy wedge resection left upper lobe consistent with acute organizing ﬁbrinous pneumonitis (AFOP)
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our institutions protocol when he presented to clinic
with dry cough, dyspnea, and oxygen saturations in mid
60% on room air. A chest CT demonstrated signiﬁcant
multifocal nodular opacities and ground glass in all lung
ﬁelds (ﬁgure 1) as well as enlargement of axilla, sub
pectoral and mediastinal lymph nodes. He underwent a
non-diagnostic bronchoscopy followed by VATS left up-
per lobe and left lower lobe wedge resections. The pa-
thology revealed acute organizing ﬁbrinous pneumonitis
(AFOP) (ﬁgure 2). He was intubated in the intensive care
unit for 2 days after VATS wedge resection procedure.
Therapy for AFOP was initiated methylprednisolone
1000mg daily in divided doses along with tacrolimus.
Several days later etanercept 25mg SQ twice weekly was
initiated because patient was not improving his
oxygenation. He received a total of 8 doses of eta-
nercept. His recovery was complicated by prolonged
pneumothorax and pneumomediastium requiring a
pigtail catheter. He returned to the operating room for
decortication, mechanical pleurodesis and chest tube
placement. Eight days postoperatively the chest tube
was removed. He was weaned of oxygen in seven days.
Repeat chest CT demonstrated improved multifocal
airspace disease (ﬁgure 1) and he is still without oxygen
as of September 2014.
Discussion: To the best of our knowledge this is the ﬁrst
case demonstrating the successful treatment of AFOP, a
sub-type of pulmonary chronic GVHD, with etanercept.
Etanercept is an inhibitor of tumor necrosis factor-alpha
(TNF-alpha).Figure 2. CT images before509
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University Hospital, Stockholm, SwedenGraft versus host disease (GvHD) is a common and severe
complication after allogeneic stem cell transplantation.
During pregnancy, the placenta and the fetal membranes
function as an immunological barrier, protecting the fetus
from the mother’s immune system.We have isolated stromal
cells from the decidual layer of term placentas. These
decidual stromal cells (DSCs) are of maternal origin, and
strongly inhibit the alloreactivity of T-cells in vitro. The effect
is mainly contact dependent, and decreases the production
of several key cytokines involved in the cytokine storm
promoting the continuation of GvHD.
To investigate the effect of DSCs on acute GvHD we
enrolled 32 patients diagnosed with acute GvHD grade 2-4
and clinically non-responsive to standard therapy. The pro-
tocol was changed after 17 patients, the DSCs were then
thawed and infused in infusion solution with albumin
instead of AB-plasma and given repeatedly and earlier uponand after etanercept
Figure 1.
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(group 1 n¼17 and group 2 n¼15), which were compared to
matched historical controls (n¼54). We also performed a
retrospectively corrected analysis of steroid refractivity at
day 7 after start of corticosteroids in the different groups.
Group 1 received a median of 1 (range 1-5) infusion on
day 11 (range 1-31) after standard treatment compared to
group 2, who received a median of 2 infusions (range 1-4,
p<0.05) on day 6 (range 0-26, ns). No adverse events related
to the treatment were observed. At 4 weeks after treatment,
60% of the patients in group 1 had responded to the treat-
ment. In contrast, all patients in group 2 responded
(p<0.05). All patients in the treatment groups received
fungal prophylaxis.
The overall cumulative survival (OS) at 365 days was 78%
for group 2, as compared to 47% for group 1 and 28% for the
controls (p<0.001). When the groups were corrected for
steroid-refractivity, the OS was 76% for group 2, 38% for
group 1 and 6% for the controls (p<0.001). In the control
group, the risk of dying from GvHD was 51%, compared to
48% for group 1, whereas none of the three deceased patients
in group 2 died from GvHD (p<0.005). In the last 18 months,
no patients have died from acute GvHD at our center.
In conclusion, DSCs might be an effective treatment of
GvHD. The infusion should be prepared in albumin, given as
early as possible and in repeated doses. All patients should
receive fungal prophylaxis and should be closely monitored
for any infectious complications.Figure. Kaplan-Meier curve for the probability of relapse according to PIR-
CHE-I numbers. Patients presenting above median PIRCHE-I have a signiﬁ-
cantly reduced probability of relapse compared to those presenting lower
numbers of PIRCHE-I.510
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Introduction: Unrelated Cord Blood Transplantation (UCBT)
provides a curative therapy for patients with hematologicalmalignancies (and a variety of benign disorders). HLA-mis-
matched UCBT is associatedwith improved leukemia control.
The aim of this study was to investigate whether indirect
recognition of the mismatched HLA provides an explanation
for this improved graft-versus-leukemia (GVL) effect, and
can be used to identify donors with optimal GVL properties
without impacting probability on graft-versus-host disease
(GVHD).
Methods: All consecutive pediatric patients transplanted
from 2004 for various diseases after myeloablative condi-
tioning (either Busulfan-based or TBI-based), with an UCBT
were included. The probability of indirect recognition was
predicted by determining the number of Predicted Indirectly
ReCognizable HLA Epitopes (PIRCHE), as described previ-
ously (K. A. Thus, et al., BBMT 2014). Patients were divided
into two groups, according to the numbers of PIRCHE pre-
sented by HLA class I and II (PIRCHE-I and eII, respectively),
above and at or below median number of PIRCHE. Primary
endpoint: relapse. Secondary endpoints: acute- and chronic
GVHD, disease-free survival (DFS), and transplant-related
mortality (TRM). Cox proportional hazard models were used
for analyses.
